Stocks moved across sectors in premarket trading on a mix of company-specific catalysts, including changes to mortgage pricing at Fair Isaac tied to Fannie Mae and Freddie Mac, new deal activity around AMD, and fresh guidance signals from CarMax’s earnings report.
Notable movers included Fair Isaac, which fell sharply after comments from a Federal Housing Finance Agency official on mortgage pricing methodology; AMD, which rose after agreeing to acquire AI firm World Labs; and Summit Therapeutics, which surged following a $2 billion strategic investment announcement from AstraZeneca.
Key takeaways
- Fair Isaac shares fell 18% as mortgage pricing changes signaled a shift in how VantageScore would be incorporated alongside existing FICO pricing.
- AMD shares rose more than 1% after it agreed to buy AI firm World Labs for $8.2 billion, adding to its AI ambitions.
- Summit Therapeutics jumped 18% on $2 billion in investment from AstraZeneca tied to equity and clinical collaboration.
- Navitas Semiconductor climbed 8% after winning a government contract for next-generation ultra-high-voltage silicon carbide (SiC) chips.
- CarMax gained more than 6% after reporting second-quarter results that beat analyst expectations.
What drove the premarket moves
Fair Isaac: mortgage pricing reconfiguration sparks selloff
Fair Isaac shares plunged in premarket after Federal Housing Finance Agency director Bill Pulte said Fannie Mae and Freddie Mac would move to a single mortgage pricing grid and incorporate VantageScore alongside the existing FICO Classic pricing framework. According to Pulte’s post on X, the change is intended to simplify mortgage pricing “following feedback from lenders and consumers,” shifting from two separate pricing grids to one. Investors appeared to interpret the announcement as a meaningful impact to how credit scoring models could affect pricing usage, which weighed on sentiment toward Fair Isaac.
AMD: acquisition lifts chipmaker sentiment
AMD traded higher after announcing the acquisition of AI firm World Labs for $8.2 billion. The deal adds an AI-focused asset to AMD’s platform strategy, and premarket buying suggested investors viewed the transaction as supportive of demand linked to artificial intelligence and related compute workloads.
Summit Therapeutics: AstraZeneca investment adds momentum
Summit Therapeutics surged after it announced a $2 billion strategic equity investment from AstraZeneca, alongside a clinical collaboration. The company said in a release that it has established agreements with AstraZeneca for the investment and a collaboration focused on ivonescimab and sonesitatug vedotin. These are described by the company as cancer-focused drugs, and investors appeared to view the funding as a potential acceleration for development and program execution.
Navitas Semiconductor: government contract supports SiC roadmap
Navitas Semiconductor gained after securing a government contract to develop next-generation chips. According to the company’s statement, the contract marks “a significant milestone” in advancing ultra-high-voltage silicon carbide (SiC) power devices. For markets tied to power efficiency and electrification, government program awards can be a near-term visibility boost, which likely contributed to the premarket jump.
CarMax: earnings beat drives premarket strength
CarMax climbed more than 6% after reporting better-than-expected second-quarter results. The used vehicle retailer earned $1.16 per share on revenue of $7.88 billion. Analysts polled by FactSet expected profit of 73 cents per share on revenue of $7.09 billion, underscoring both earnings and sales outperformance versus consensus.
Market reaction and what investors appeared to focus on
Across the names, premarket trading emphasized two themes: credit and mortgage pricing methodology as a potential structural variable, and deal-and-development catalysts that can change forward expectations more quickly than macro data.
The sharp drop in Fair Isaac contrasted with gains elsewhere as investors seemed to weigh how scoring model integration in U.S. mortgage pricing could affect demand for credit-related services. Meanwhile, the positive reaction to AMD and Summit Therapeutics suggested market participants were more willing to reprice companies on concrete corporate actions—an acquisition with AI relevance and a large strategic investment tied to drug development.
CarMax’s move also reflected a classic earnings reaction: the company’s reported profitability and revenue exceeded consensus, offering a clearer read-through for near-term margins and operating momentum.
Other notable premarket movers
Bloomin’ Brands rose about 5% after JPMorgan upgraded the stock to neutral from underweight. The bank pointed to operational changes implemented by the company, including a new steak lineup and a “reduction table to server ratio during peak hours from 6 tables to 4 tables,” according to the brokerage’s view.
SpaceX climbed roughly 1% after TD Cowen initiated coverage with a buy rating. Analysts highlighted growth drivers tied to artificial intelligence and space exploration as key themes for the company.
Bigger picture: what to watch next
With premarket momentum driven largely by company-specific announcements, investors may look next for follow-through on guidance and implementation details—particularly around mortgage pricing frameworks affecting credit scoring utilization. For the stocks in focus, upcoming catalysts include continued earnings and company updates, as well as broader market drivers such as interest-rate expectations and credit conditions that can influence mortgage-related financial services and consumer demand for vehicles.
